CONCLUSIONS: Based on aggregate clinical trial-level data an association between SU and gout flare could not be confirmed. However, based on observational ecological study design data -including longer duration extension studies -SU<6mg/dL was associated with reduced gout flares. 4 The Outcome Measures in Rheumatology (OMERACT) gout working group identified serum urate (SU) as a mandatory outcome measure in gout studies [1] . Reduction of SU to <6mg/dL is recommended by both ACR and EULAR as a key goal in the long-term gout management [2, 3] . The use of SU as a treatment target and as an outcome measure, has become controversial, in light of the American College of Physician Gout Guidelines which advocate a "treat-to symptom", rather than a "treat-to-target SU" approach to gout management [4] .
SU is currently the most common primary efficacy outcome measure in clinical trials of urate lowering therapies (ULT) including phase III trials required for regulatory approval of new ULTs [5] [6] [7] [8] . The relevance of SU as a primary outcome measure implies that achievement of a target SU is associated with clinically meaningful and patient-important outcomes in gout such as a reduction in the number of flares and/or tophus size or number; that is, SU is implicitly considered to be a surrogate endpoint.
The direct use of patient-important features as outcome measures in trials is challenging as they are likely to require very large sample sizes or long-term follow-up for a benefit to be observed. A surrogate end point may be defined as an "objective" laboratory measurement or a physical sign used as a substitute for a clinically meaningful end point that measures directly how a patient feels, functions, or survives [9] . Whereas the related biomarker term can be defined as "a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes or pharmacologic responses to a therapeutic intervention" [10, 11] . While the use of surrogate endpoints allows for smaller, shorter, and less costly clinical trials there have been concerns about the validity of statistical methods used to evaluate relationships between the surrogate endpoint and the clinical outcomes. We have previously reported 5 that SU fulfils the OMERACT 9 soluble biomarker requirements in terms of performance criteria [12] . There is limited evidence that changes in SU or achieving target SU are associated with changes in patient-reported outcomes in gout [12] . We hypothesized that a reduction in SU will be associated with improvement in clinically meaningful patient important outcomes such as gout flares and tophus size/number, sufficiently strongly to confirm that SU is indeed a valid surrogate.
The objectives of this study were 1) to determine the strength of the relationship between SU and clinically relevant outcomes, including gout flares, tophi, health related quality of life (HRQoL), pain and function, using meta-regression of randomized controlled trials (RCTs); and 2) to evaluate whether SU can be considered a surrogate endpoint for clinically relevant outcomes in people with gout as defined by the Biomarker-Surrogacy Evaluation Schema (BSES) 3 framework [13] .
PATIENTS and METHODS
The protocol for the systematic review and meta-regression analyses was prepared according to PRISMA-P recommendations [14] and prospectively registered on PROSPERO (CRD42016026991). Full details of the protocol have been published previously [15] but are outlined in brief below.
Data Sources and Searches
PubMed, EMBASE, the Cochrane Library including the Cochrane Central Register of Controlled Trials (CENTRAL) and Cochrane Database of Systematic Reviews were searched up to October 2017. The search was limited to English language studies in humans, but not limited by year of publication.
Study Selection
The eligibility criteria for objective 1 was any RCT comparing any urate lowering therapy (alone or in combination) in people with gout with any control or placebo, with a minimum duration of three months. For objective 2, controlled clinical trials, open label extension (OLE) studies comparing urate lowering therapy (alone or in combination) in patients with gout with any control or placebo, or longitudinal observational studies of gout with a minimum duration of three months were included as well as the RCTs. Data available only in abstract form were excluded.
Data Collection and Study Appraisal
Standardized data elements were extracted from each study by two independent reviewers (LS, MM) and disagreements resolved by discussion (WT, RC). RCTs were assessed for methodological quality using the Cochrane Risk of Bias tool [16] . If at least one of the domains was rated as inadequate, the trial was considered at high risk of bias.
If all domains were judged as low, the trial was considered at low risk of bias.
Otherwise, the trial was considered as having unclear risk of bias.
Grading of Recommendations Assessment, Development and Evaluation (GRADE)
criteria was used to rate the overall quality of the evidence based on both the apparent risk of bias, publication bias, imprecision, inconsistency, indirectness, and magnitude of effect [17] .
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Data Synthesis and Analysis
For the purpose of meta-regression, the independent variable of major interest was defined as the difference between proportions (in each group) achieving SU <6mg/dL, at three months follow-up. Where three month values were not available, the value at six months or 12 months (in order of preference) was used. An attempt was made to use the average change in SU from baseline, but data in the available trials was not reported consistently enough to enable an appropriate analysis. According to the protocol the prespecified clinically important endpoints (dependent variables) were defined as follows: 1) major outcome: gout flares, 2) minor outcomes: size of sentinel tophus (if size was not measured, number, or presence/absence in order of preference) and pain at final study visit. Exploratory analyses were undertaken with the following clinically important outcomes: HRQoL (Short Form [SF] 36), patient global assessment of disease activity, and physical disability (activities limitation; e.g., Health Assessment Questionnaire [HAQ]). Cohort studies were summarized by narrative review.
Statistical Analysis
Randomization is essential for the causal surrogacy relationship; therefore, only net changes from RCTs were included in the main meta-regression analyses. According to the primary objective of the project we evaluated the surrogacy of the difference between proportions achieving target on SU as a 'predictor' of the relative risk of developing a gout flare using meta-regression of RCTs. Where more than two arms from a single trial were present, the by-arm results were contrasted with a single 'control' comparator; i.e., in trials with a true placebo, the placebo is the control comparator.
Thus, in studies with multiple arms, the numbers of patients in the placebo groups were divided by the number of active treatment arms, avoiding double counting of patients and yielding more correct (conservative) estimates. In trials without placebo, the control comparator was defined as the intervention arm that best reflects usual care, in most cases allopurinol.
The treatment effects (i.e. relative risk of developing a flare) were expressed as risk ratios derived from the reported statistics (either derived from continuous or dichotomous outcomes). We conducted meta-regression analyses using SAS software (PROC MIXED version 9.4; SAS Institute Inc., Cary, NC, USA), based on a restricted maximum likelihood estimation of the between-study variance [18] . Association between the variables were analyzed by simple correlation between gout flare rate either as a proportion or converted into events over patient-years (dependent variable[s]), scattered against the proportion achieving SU <6mg/dL and the duration of the trial..
It has been suggested that gout flares take many months to reduce in frequency and stop altogether after achieving target SU. Therefore, we hypothesized that the large number of short term studies (≤12months duration) and studies where the proportion of individuals achieving target SU and the proportion having a flare were in close temporal proximity may obscure any relationship. To examine this a post-hoc analysis was undertaken with the six studies where the ratio of the time in months at which the proportion of individuals having a flare was reported/time in months at which the proportion of individuals achieving target SU was <2 (included studies denoted by * in Table 1 ).
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BSES evaluation
The BSES-3 framework represents the currently best available approach to validate a biomarker as a surrogate endpoint. BSES-3 contains four domains: study design, target outcome, statistical evaluation, and generalizability. It also specifies the kind of statistical association required to justify the link between biomarker and clinical endpoint being sufficiently strong to consider the biomarker as a surrogate endpoint [19, 20] . This framework has been used to show that diastolic and systolic blood pressure are valid surrogate endpoints for stroke risk reduction [13] and to evaluate progression-free survival in metastatic renal cell carcinoma [21] .
The BSES-3 framework was applied after the meta-regression analysis. It requires a validated surrogate endpoint to have a combined score of at least nine, with at least one domain rank three and the remainder of at least rank two, with a minimum threshold rank of at least two across all domains. If the threshold criteria are not met the grade drops by one alphabetic grade. This approach prevents a high score in one domain compensating for low scores on other domains.
RESULTS
Study Selection
The systematic literature review identified 3271 records after removal of duplicates. The full-text of 94 records were reviewed after title and abstract screening. A total of ten RCTs were identified for inclusion in objective one (Figure 1) . For objective two, an additional three OLE studies and eleven observational cohort studies were identified (Figure 1 and Supplementary Figure 1) . Details of the RCTs, including overall risk of bias assessment, are outlined in Table 1 .
Relationship between serum urate and gout flares
Using the data from the RCTs only (ten trials with 17 comparisons), a total of 6010 people with gout were included in the meta-regression model. The longest RCT included was 24 months duration [6] . The pooled risk ratio (RR) suggested a small but statistically significant favorable association between the active and comparator urate lowering therapies and flare frequency (RR=0.89; 95%CI 0.83 to 0.96). The overall meta-analysis was based on some heterogeneity (between trial variance: 0.01; I 2 =29%).
Meta-regression analysis did not support any statistically significant association between the difference in proportions of individuals who achieved SU<6mg/dL and the observed flare risk ratio (z = 0.72; P=0.47); the model fit did not improve after inclusion of the individuals who achieved SU target into the model (increasing the between trial variance with 0.002; i.e. no improvement in the proportion of variance explained) (Figure 2) . By using simple linear regression only 8% of the variation in log-RR could be explained by the difference in proportions of individuals achieving SU<6mg/dL (R-square = 0.0799)
The proportion of individuals achieving SU<6mg/dL at 3 months or where 3 month values were not available, the value at 6 months or 12 months as the dependent variable and the proportion of individuals experiencing a gout flare at the study end was then included in the analysis, as well as data from three long term OLE studies. Details of the three OLE studies are outlined in Table 1 . Two studies [22] [7] included in the original RCT analysis were excluded as the proportion of individuals with flares at the end of the study was not reported. The longest study was 60 months [23] . To account for study duration, the delay between achieving target SU and reduction in gout flares studies where the proportion having a flare were in close temporal proximity may obscure any relationship only the six studies where the ratio of the time in months at which the 11 proportion of individuals having a flare was reported/time in months at which the proportion of individuals achieving target SU was <2 were included in the analysis.
Using these six studies (including 13 data points) there was an association between proportion of individuals achieving SU<6mg/dL and the observed gout flares (over patient years; Figure 3a ). Duration of ULT was also inversely associated with the proportion of patients experiencing a flare (Figure 3b) . The observational and cohort studies which examine the relationship between SU and clinically relevant outcomes have been summarized in Supplementary Table 1 . The observational studies generally report a higher number of gout flares in participants with a higher mean SU compared to a lower mean SU or in those with SU>6mg/dL compared to those with SU<6mg/dL.
Relationship between serum urate and other clinically important outcomes
Variable and inconsistent reporting of the other outcomes precluded further analysis.
Only one RCT [8] and two observational studies [24, 25] reported HRQoL with no uniformity in the data presented therefore no analysis could be undertaken. Likewise inconsistent reporting of tophus size and or number precluded appropriate analysis.
BSES evaluation
The performance of SU as a surrogate endpoint for gout flares according to the BSES3 is shown in Table 2 . SU is a level C+ surrogate endpoint for gout flares with evidence from multiple RCTs (n=10) across drugs with different mechanisms of action (e.g. xanthine oxidase inhibitors, uricosurics and recombinant uricases) in people with gout.
Using the data available, SU ranked 0 on the statistical evaluation domain meaning that it does not meet the threshold criteria of a minimum rank two across all domains thus dropping the overall grade to D+.
GRADE evaluation
Based on the GRADE approach, there was high-quality evidence to suggest that ULT will reduce SU below the treat-to-target threshold. However, there was low-quality evidence to suggest that ULT may be beneficial for the prevention of gout flares (rated down twice: serious imprecision and inconsistency with the latter not being explained by SU).
DISCUSSION
Most epidemiological investigations of etiology are observational. In ecological studies the unit of observation is the population or community; this study design can be used to explore possible associations between the occurrence of gout flares and the corresponding proportion (in the same population) who have achieved SU target. Using data from long-term studies, but not with RCTs alone, we have shown there is an association between achieving SU <6mg/dL and a reduction on the proportion of individuals experiencing a gout flare if studies are of sufficient duration. A limitation to the interpretation of ecological studies, is the potential logical fallacy in the interpretation of statistical data where inferences about the nature of individuals are deduced from inference for the group to which those individuals belong; i.e. the relationship with patient averages across trials may not be the same as the relationship for patients within trials. The phenomenon is variously referred to as 'aggregation bias', 'ecological bias', 'ecological confounding' or the 'ecological fallacy' [26] , and this cannot be investigated without individual patient data [27] . SU did not reach the threshold for a validated surrogate using the BSES3 framework primarily due to the short term nature of the RCTs.
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From an OMERACT perspective, measurement of pathophysiological manifestations is essential to assess whether or not the effect of the intervention specifically targets the pathophysiology of the health condition [28] . There is considerable biological plausibility to the concept that a reduction in SU is important in the management of gout. The cardinal clinical features of gout are intermittent flares and tophi, which are both mechanistically due to deposition of monosodium urate (MSU) crystals. Gout flares represent an acute inflammatory response to MSU crystals while the tophus represents a foreign body granulomatous reaction to larger collections of MSU crystals [29] . MSU crystals form when SU is above saturation threshold; >6.8mg/dl at pH 7.0 and temperature 37°C, and >6mg/dL at pH 7 and temperature 35°C [30] . Reduction of SU below saturation threshold results in dissolution of MSU crystals in joints thus removing the stimulus for the acute inflammatory reaction that results in gout flares [31] and resolution of tophi [32] . Mean time from onset of ULT to disappearance of tophi has been reported to be 20.8 ± 10.2 months and the lower the SU the more rapid the dissolution of the tophus [32] . Similarly, the time required for disappearance of MSU crystals from joints has been reported to range from 3 to 33 months and disappearance time correlated with the duration of gout [31] . This prolonged time to MSU crystal disappearance is consistent with continued gout flares even after achieving target SU in clinical trials of ULT [6] and suggests that the recent RCTs, the majority of which are ≤12months long may be of insufficient duration to observe a reduction in gout flares. (Table 1) . Given this short trial duration and the evidence that MSU crystal dissolution takes on average longer than the trial duration it is not surprising that we were unable to observe a statistically significant association between achieving target 0.94 (2.03) in the general practitioner-led group (P<0.001) [33] . Another two RCTs were not included in the meta-analysis; a 12 month RCT of lesinurad in combination with febuxostat which could not be included in the analysis as SU<5mg/dL was reported rather than SU<6mg/dL [34] and a 12 week RCT of the new agent arhalofenate which has dual urate lowering and anti-inflammatory properties and was thus excluded as the anti-inflammatory mechanism masked flares in the arhalofenate groups [35] . In the lesinurad study the mean (SD) number of flares per participant in the 12 months prior to study entry was 6.7 (8.2) reducing to 1.2 (2.7), 1.4 (2.5), and 0.7 (1.2) per participant in the febuxostat, lesinurad 200 mg + febuxostat, and lesinurad 400 mg + febuxostat groups, respectively between months 6 and 12 [34] . In keeping with this significantly more participants receiving lesinurad 400 mg + febuxostat achieved SU<5.0mg/dl compared with febuxostat alone of (at month six, 46.8% in the febuxostat group, 56.6% in the lesinurad 200 mg + febuxostat group, and 76.1% in the lesinurad 400 mg + febuxostat group achieved SU<5.0mg/dl ). Furthermore, data from the observational studies (supplementary table 1) are in keeping with these RCT data with a reduction in the number of gout flares over time in those treated with ULT and achieving target urate.
While these studies add weight to the argument for an association between SU and gout flares, ultimately a clinical trial of urate lowering therapy using the treat-to target SU strategy with gout flares as the primary outcome measure is required.
Whilst SU can be considered a biomarker, it did not reach the required level of evidence to be considered a surrogate according to the BSES-3 framework. This was primarily due to a lack of statistical evidence from the RCTs. Additional analyses on individual patient data from clinical trials published after the completion of the literature review and therefore not included in this analysis are underway and may provide also additional evidence and strengthen the statistical association between SU and gout flares.
There is considerable interest in biomarkers in medicine. The FDA has recently published definitions for different categories of biomarkers and surrogates [36] . To date there are no validated surrogates or other biomarkers for use in rheumatic diseases, 16 although there is considerable interest in identification of soluble biomarkers for structural joint change. The method utilized in this study provide an approach for validating surrogacy that can potentially be used for the assessment of biomarkers in other rheumatic diseases in the future.
There were significant limitations in performing this analysis. Although OMERACT has agreed the outcome domains for chronic gout which include SU, gout flares, HRQoL and tophus burden [37], there was considerable variability in the reporting of these domains. The instruments used for measuring these outcomes and the exact manner in which they should be reported has not been formally validated. For example, gout flares were self-reported in the majority studies included in this analysis. There was also variability in the way SU was reported, including various combinations of percentage at target SU, percentage change in SU and mean SU [38] . Validation of instruments to assess important clinical outcomes is required and it is pleasing to note that a definition of gout flare has recently been validated [39, 40] . Furthermore, the majority of studies were not placebo-controlled. While this is appropriate from an ethical perspective, the lack of placebo potentially obscured any relationship between SU and gout flares in this analysis.
Despite the current failure of SU to reach the threshold for validation as a surrogate using the BSES-3 framework, the evidence is supportive of a relationship between SU and gout flares. Any clinical trial with gout flares as the primary endpoint is likely to be many years away. While a more definitive answer about the relationship is required, the treat-to-target SU as advocated by ACR and EULAR to improve clinically important outcomes such as flares still appears to be appropriate [2, 3] . 
BIOMARKER-SURROGATE EVALUATION
